Vitreo-Retinal Medical Group, INC.
Vitreo-Retinal Medical Group, INC. was paid $3.42M by Medicaid between Jan 2018 and Oct 2024, across 12 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 60% of everything it billed.
FAIRFIELD, CA 94534
Next to other Ophthalmology Physician providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,140 | $196K | |
| 2019 | 1,807 | $175K | |
| 2020 | 1,792 | $294K | |
| 2021 | 2,700 | $564K | |
| 2022 | 2,691 | $877K | |
| 2023 | 2,909 | $907K | |
| 2024incomplete | 2,043 | $406K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 67028 | Intravitreal injection of a pharmacologic agent | 60% | 5,642 | 4,363 | $2.06M |
| J0178 | Injection, aflibercept, 1 mg | 28% | 603 | 576 | $955K |
| 92134 | 5.3% | 6,017 | 5,755 | $180K | |
| J2778 | Injection, ranibizumab, 0.1 mg | 1.8% | 89 | 86 | $60K |
| 92235 | 1.3% | 729 | 714 | $45K | |
| 92250 | 1.0% | 886 | 868 | $35K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | <1% | 724 | 705 | $21K |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | <1% | 31 | 24 | $20K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 212 | 198 | $16K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 279 | 267 | $16K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 687 | 674 | $8K |
| J7999 | Compounded drug, not otherwise classified | <1% | 183 | 174 | $4K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Vitreo-Retinal Medical Group, INC. | Stockton, CA | $11.61M |
| Vitreo-Retinal Medical Group, INC. | Modesto, CA | $4.17M |
| Vitreo-Retinal Medical Group, INC. | Sacramento, CA | $815K |
| Vitreo-Retinal Medical Group INC | Yuba City, CA | $505K |
| Vitreo-Retinal Medical Group, INC. | Chico, CA | $302K |
| Vitreo-Retinal Medical Group, INC. | Sacramento, CA | $215K |
| Vitreo-Retinal Medical Group, INC | Folsom, CA | $154K |
| Vitreo-Retinal Medical Group, INC | Merced, CA | $123K |
| Vitreo-Retinal Medical Group INC | Elk Grove, CA | $69K |
| Vitreo-Retinal Medical Group, INC | Roseville, CA | $35K |
| Vitreo-Retinal Medical Group, INC. | Grass Valley, CA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.